Why a consensus conference on hormone replacement therapy and the cardiovascular system?

Maturitas

Volumn 47, Issue 4, 2004, Pages 245-253

  Benagiano, G ^a   Farris, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer risk; Cardiovascular risk; Hormone replacement therapy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DESOGESTREL; ESTRADIOL; ESTROGEN; GESTAGEN; GESTODENE; HORMONE; LEVONORGESTREL; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TESTOSTERONE;

ALOPECIA; BREAST CANCER; CANCER INVASION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG TOLERABILITY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LAW SUIT; MASTALGIA; MENOPAUSAL SYNDROME; META ANALYSIS; METRORRHAGIA; PREGNANCY; SIDE EFFECT; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; CONSENSUS DEVELOPMENT CONFERENCES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH EDUCATION; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; WOMEN'S HEALTH;

EID: 1942471923     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.11.012     Document Type: Conference Paper

References (27)

1. Writing Group for the Women Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
2. ACOG Today: advertisement. 2002;46:8-9.
3. Kaufman M. Drugmaker to relabel estrogen. Internat Herald Trib (Paris) 7 October 2002.
4. Brody JE. Finding the facts about hormones. Internat Herald Trib (Paris) 5 September 2002.
5. Association of Professors of Gynecology and Obstetrics (USA). Improving quality of life during menopause. APGO (Crofton, USA); 2002.
6. Marsh B. HRT: why it does you more harm than good. Daily Mail (London) 20 September 2002.
7. Kolata G. Scientists debating future of hormone replacement. Internat Herald Trib (Paris) 23 October 2002.
8. Cookson C. British medical research body abandons HRT clinical study. Financial Times (London) 24 October 2002.
9. Sartwell P.E., Masi A.P., Arthes G., Greene G.R., Smith H.E. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am. J. Epidem. 90:1969;365-380.
10. Christie T, Contributions from the pharmaceutical industry. In: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry. Hum Reprod 1987;2:241-58.
11. Vessey M., Baron J., Doll R., Mc Person K., Yeates D. Oral contraceptives and breast cancer: final report of an epidemiological study. Br. J. Cancer. 47:1983;455-462.
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological study. Lancet 1996;347:1713-27.
13. Tikkanen M.J., Nikkila E.A. Oral contraceptives and lipoprotein methabolism. J. Reprod. Med. 31:1986;898-905.
14. Kuhl R. Comparative pharmacology of newer progestogens. Drugs. 51:1996;188-216.
15. Pike M.C., Henderson B.E., Krailo M.D., Duke A., Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 2:1983;926-930.
16. WHO World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-88.
17. Dillner L. Pill scare linked to rise abortions. BMJ. 312:1996;996.
18. Ashraf H. UK high court dismisses risk of VTE in "pill" test case. Lancet. 360(9330):2002;391.
19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
20. Kannel W., Hjortland M.C., McNamara P.M., Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. 85:1976;447-452.
21. Goldzieher JW. Letter to the Editor, in reference to the article by McDonough PG, editor. The randomized world is not without its imperfections reflections on the Women's Health Initiative Study. Fertil Steril 2003;79:1258.
22. Rosano G.M., Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. Cardiol. Rev. 10:2002;51-60.
23. Grodstein F., Mansour J.E., Stapley M.J. Postmenopuasal hormone use and secondary prevention of coronary events in the Nurse's Health Study: a prospective observational study. Ann. Int. Med. 135:2001;1-8.
24. Goodman N., Goldzieher J.W., Ayala K. Critique of the WHI study of HRT as primary prevention of CHD in postmenopausal women. Menopause Med. 10:2003;1-4.
25. Mc Donough P.G. The randomized world is not without imperfections: reflections on the Women's Health Initiative Study. Fertil. Steril. 78:2002;951-956.
26. Hulley S., Grady D., Bush T., Furberg K., Herrington D., Riggs B.et al. Heart and Estrogen/Progestogen Replacement Study (HERS) Research Group Randomized trial of oestrogen plus progestin for secondary prevention of coronary hearth disease in postmenopausal women. JAMA. 280:1998;605-613.
27. Decensi A., Omodei U., Robertson C., Bonanni B., Guerrieri-Gonzaga A., Ramazzotto F.et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation. 106:2002;1224-1228.